ALD02

ALD02 is an investigational cardiac cell therapy being developed by Alder Therapeutics. It is designed to restore heart function in patients with heart failure, a leading cause of death worldwide. Preclinical studies have shown that ALD02 improves heart function in animal models of induced heart disease without causing fatal arrhythmias and demonstrates significant thickening of the ventricular wall. The therapy aims to offer advantages over existing cell therapies for heart failure, including improved efficacy and manufacturing scalability. The specific mechanism of action has not been disclosed, but as a cardiac cell therapy, it likely involves the transplantation or delivery of regenerative cells to repair or replace damaged myocardial tissue[1][4].